Abstracts tagged "risk assessment and systemic sclerosis"

Abstract Number: 1693 • 2017 ACR/ARHP Annual Meeting
To What Extend Do Auto-Antibodies Help to Identify High-Risk Patients in Systemic Sclerosis?
Maaike Boonstra¹, Jaap Bakker², Maarten K. Ninaber³, Nina Ajmone Marsan⁴, Tom W.J. Huizinga⁵ and Jeska K. de Vries-Bouwstra⁶, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands, ³Pulmonology, Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ⁴Heart and Lung Center, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands
Background/Purpose: In Systemic Sclerosis tight monitoring during the first years of disease is required in order to detect organ complications timely. Although a clear pathophysiologic…
Abstract Number: 825 • 2015 ACR/ARHP Annual Meeting
Subclinical Atherosclerosis and Estimation of Cardiovascular Risk in Systemic Sclerosis
Gulsen Ozen¹, Fatmanur Korkmaz², Murat Sunbul³, Rabia Deniz⁴, Kursat Tigen³, Pamir Atagunduz¹, Nevsun Inanc¹ and Haner Direskeneli¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Cardiology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁴Marmara University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: During the last decade, it has been shown that cardiovascular disease (CVD) in systemic sclerosis (SSc) is increased and accounts for ~30% of the…
Abstract Number: 1899 • 2015 ACR/ARHP Annual Meeting
Aortic Stenosis Is Increased in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Compared to Other Forms of Pulmonary Arterial Hypertension
María Martín López¹, Otto Martin Olivas Vergara², Mario Rodríguez³, Carmen D Merino⁴, Carmen Jiménez^5,6, Estibaliz Loza⁷, Pilar Escribano^5,6, Loreto Carmona⁸ and Patricia E. Carreira², ¹RHEUMATOLOGY, Hospital Universitario 12 de Octubre, Madrid, Spain, ²Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Fundación Hospital de Alcorcón, Madrid, Spain, ⁵Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Research Unit. Sociedad Española de Reumatología, Madrid, Spain, ⁸Instituto de Salud Musculoesquelética, Madrid, Spain
Background/Purpose: Degenerative aortic stenosis (DAS) is the most common form of valvular heart disease associated with advancing age. DAS pathophysiology has not been clearly elucidated,…
Abstract Number: 2997 • 2014 ACR/ARHP Annual Meeting
Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients
Robyn T. Domsic¹, Svetlana I. Nihtyanova², Mary Lucas³, Stephen R. Wisniewski⁴, Michael J. Fine⁵, C. Kent Kwoh⁶, Christopher P. Denton⁷ and Thomas A. Medsger Jr.⁸, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵General Medicine, University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, ⁶1501 N. Campbell Avenue, Room 8303, The University of Arizona Arthritis Center, Tucson, AZ, ⁷Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ⁸Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose : Knowledge of mortality risk and predictors is important in systemic sclerosis (SSc) patient care and clinical trial design. There is no validated 5-year…
Abstract Number: 2709 • 2014 ACR/ARHP Annual Meeting
Could a Fibroblast-Free Environment Protect the Microcirculation in Systemic Sclerosis? Evidence from Retinal Vascular Imaging Research
Evaggelia K. Aissopou¹, Vasiliki-Kalliopi Bournia¹, Athanase D. Protogerou¹, Stylianos Panopoulos¹, Theodore G. Papaioannou², Panayiotis G. Vlachoyiannopoulos¹, Marco Matucci-Cerinic³ and Petros P. Sfikakis¹, ¹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²Biomedical Engineering Unit, First University Dept. of Cardiology, Hippokration Hospital , Athens University Medical School, Athens, Greece, ³Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Background/Purpose: A primary endothelial cell dysfunction is thought to be involved in systemic sclerosis (SSc)-associated fibroproliferative vasculopathy of the microcirculation and small arterioles, even in…
Abstract Number: 696 • 2012 ACR/ARHP Annual Meeting
Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database
Patricia E. Carreira¹, Loreto Carmona², Beatriz E. Joven³, Christopher P. Denton⁴, Yannick Allanore⁵, Ulrich A. Walker⁶, Marco Matucci-Cerinic⁷, Ulf Müller-Ladner⁸ and Eustar⁹, ¹Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ²Health Sciences School, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, ³Rheumatology, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Madrid, Spain, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁵Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁶Rheumatology, Universitäts-Poliklinik, Felix-Platter Spital, Basel, Switzerland, ⁷Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, ⁸Abt. f. Rheumatologie u. klinische Immunologie, Osteologie, Physikalische Therapie, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, ⁹Florence
Background/Purpose: to identify risk factors for early mortality in a large group of recently diagnosed systemic sclerosis (SSc) patients Methods: EUSTAR collects prospectively the Minimal…
Abstract Number: 698 • 2012 ACR/ARHP Annual Meeting
External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients
Robyn T. Domsic¹, Svetlana Nihtyanova², Stephen R. Wisniewski³, Michael J. Fine⁴, C. Kent Kwoh⁵, Christopher P. Denton⁶ and Thomas A. Medsger Jr.⁷, ¹Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology, Royal Free Hospital, Medical School, London, England, ³Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴General Medicine, University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, ⁵School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁷Medicine/Rheumatology, Univ of Pittsburgh, Pittsburgh, PA
Background/Purpose: The ability to risk stratify patients for short term mortality is important in SSc patient care and clinical trial design; but there is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].